Seven Fleet Capital Management LP Buys 161,237 Shares of Revolution Medicines, Inc. $RVMD

Seven Fleet Capital Management LP boosted its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 199.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 242,029 shares of the company’s stock after buying an additional 161,237 shares during the quarter. Revolution Medicines accounts for about 7.5% of Seven Fleet Capital Management LP’s holdings, making the stock its 3rd biggest holding. Seven Fleet Capital Management LP’s holdings in Revolution Medicines were worth $45,327,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Contravisory Investment Management Inc. purchased a new position in shares of Revolution Medicines during the 2nd quarter worth approximately $32,000. ABS Investment Management LLC purchased a new stake in Revolution Medicines in the second quarter valued at approximately $337,104,000. Johnson Financial Group Inc. purchased a new stake in Revolution Medicines in the second quarter valued at approximately $37,000. Northwestern Mutual Wealth Management Co. acquired a new position in Revolution Medicines during the second quarter worth $41,000. Finally, Silvant Capital Management LLC acquired a new position in Revolution Medicines during the second quarter worth $41,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: The FDA approval expands Revolution Medicines beyond clinical development and opens a potentially significant revenue opportunity in a cancer with substantial unmet treatment needs. The drug’s accelerated review and favorable efficacy profile reinforce investor confidence in the company’s RAS/MAPK-focused platform. Reuters FDA approval article
• Positive Sentiment: Management priced RASONQUE at approximately $39,800 per month, establishing a high-value commercial product and giving investors an initial benchmark for potential sales. RASONQUE pricing article
• Positive Sentiment: TD Cowen upgraded RVMD to “strong buy,” while other analysts have maintained bullish ratings and price targets above recent trading levels. Institutional ownership and reported purchases by some funds also provide supportive sentiment.
• Neutral Sentiment: The stock’s reaction has been relatively restrained despite the approval, likely because investors had anticipated the decision and RVMD already trades at an elevated valuation after a substantial run-up.
• Negative Sentiment: The $39,800 monthly list price could intensify scrutiny from insurers, policymakers and patients, potentially limiting access or slowing adoption. This pricing concern may be offsetting some of the enthusiasm surrounding the FDA decision. Pricing impact article
• Negative Sentiment: Insider Mark Goldsmith sold 80,000 shares for about $16.7 million, reducing his holdings by roughly 23%. Although one insider transaction is not necessarily a change in fundamentals, it can create a modest sentiment overhang after the stock’s sharp appreciation. Insider sale article

Revolution Medicines Price Performance

Revolution Medicines stock opened at $215.44 on Thursday. The firm has a market cap of $46.18 billion, a PE ratio of -24.43 and a beta of 1.39. Revolution Medicines, Inc. has a 52-week low of $35.64 and a 52-week high of $220.34. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. The company’s 50 day moving average is $191.27 and its two-hundred day moving average is $147.30.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the prior year, the firm earned ($1.31) EPS. On average, research analysts expect that Revolution Medicines, Inc. will post -8.82 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Sushil Patel sold 5,580 shares of Revolution Medicines stock in a transaction on Monday, June 29th. The stock was sold at an average price of $187.99, for a total value of $1,048,984.20. Following the completion of the transaction, the director directly owned 21,656 shares in the company, valued at approximately $4,071,111.44. This trade represents a 20.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mark A. Goldsmith sold 80,000 shares of Revolution Medicines stock in a transaction on Friday, August 21st. The shares were sold at an average price of $209.20, for a total value of $16,736,000.00. Following the completion of the transaction, the insider owned 267,330 shares of the company’s stock, valued at approximately $55,925,436. This trade represents a 23.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 212,497 shares of company stock valued at $38,206,486. 7.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on RVMD shares. Piper Sandler lifted their price objective on Revolution Medicines to $172.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Wedbush boosted their price objective on Revolution Medicines from $192.10 to $201.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a research note on Friday, July 17th. HC Wainwright restated a “buy” rating and set a $195.00 target price on shares of Revolution Medicines in a report on Monday, July 6th. Finally, Guggenheim lifted their target price on Revolution Medicines from $235.00 to $240.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $167.89.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.